Details of the Drug

General Information of Drug (ID: DMZVMKF)

• Drug Name: Alfuzosin
• Synonyms: Alfusosine; Alfuzosina; Alfuzosine; Alfuzosinum; Alphuzosine; Alfuzosina [Spanish]; Alfuzosine [French]; Alfuzosinum [Latin]; Alfuzosin (INN); Alfuzosin [INN:BAN]; Xatral (TN); N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide; N-(3-((4-Amino-6,7-dimethoxy-2-quinazolinyl)methylamino)propyl)tetrahydro-2-furancarboxamide; N-{3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)(methyl)amino]propyl}tetrahydrofuran-2-carboxamide

Indication

Disease Entry	ICD 11	Status	REF
Benign prostatic hyperplasia	GA90	Approved	[1]
Multiple sclerosis	8A40	Approved	[2]
Urinary retention	MF50.3	Approved	[2]

• Therapeutic Class: Antihypertensive Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 389.4
  Logarithm of the Partition Coefficient (xlogp); 1.7
  Rotatable Bond Count (rotbonds); 8
  Hydrogen Bond Donor Count (hbonddonor); 2
  Hydrogen Bond Acceptor Count (hbondacc); 8
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 194 mcgh/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 13.6 mcg/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 8 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
  Bioavailability: The bioavailability of drug is 64% [3]
  Clearance: The renal clearance of drug is 30 mL/min [3]
  Elimination: Following oral administration of a radiolabeled alfuzosin solution, the detection of radioactivity after one week was 69% in the feces and 24% in the urine [3]
  Half-life: The concentration or amount of drug in body reduced by one-half in 10 hours [3]
  Metabolism: The drug is metabolized via the hepatic [3]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3354 micromolar/kg/day [5]
  Unbound Fraction: The unbound fraction of drug in plasma is 0.14% [6]
  Vd: The volume of distribution (Vd) of drug is 3.2 L/kg [3]
• Chemical Identifiers:
  Formula: C19H27N5O4
  IUPAC Name: N-[3-[(4-amino-6,7-dimethoxyquinazolin-2-yl)-methylamino]propyl]oxolane-2-carboxamide
  Canonical SMILES: CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC
  InChI: InChI=1S/C19H27N5O4/c1-24(8-5-7-21-18(25)14-6-4-9-28-14)19-22-13-11-16(27-3)15(26-2)10-12(13)17(20)23-19/h10-11,14H,4-9H2,1-3H3,(H,21,25)(H2,20,22,23)
  InChIKey: WNMJYKCGWZFFKR-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 2092
  ChEBI ID: CHEBI:51141
  CAS Number: 81403-80-7
  DrugBank ID: DB00346
  TTD ID: D09MWJ
  VARIDT ID: DR01382
  ACDINA ID: D00018
• Repurposed Drugs (RPD): Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor alpha-1D (ADRA1D)	TT34BHT	ADA1D_HUMAN	Antagonist	[7]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Breast cancer resistance protein (ABCG2)	DTI7UX6	ABCG2_HUMAN	Substrate	[8]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Alpha-1A adrenergic receptor (ADRA1A)	OTUIWCL5	ADA1A_HUMAN	Protein Interaction/Cellular Processes	[9]
Alpha-1B adrenergic receptor (ADRA1B)	OTSAYAFD	ADA1B_HUMAN	Protein Interaction/Cellular Processes	[10]
Alpha-1D adrenergic receptor (ADRA1D)	OTW2CD1O	ADA1D_HUMAN	Protein Interaction/Cellular Processes	[10]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Alfuzosin

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Terazosin.	Prostate hyperplasia [GA90]	[11]
Tamsulosin	DM5QF9V	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Tamsulosin.	Prostate hyperplasia [GA90]	[11]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Silodosin.	Prostate hyperplasia [GA90]	[11]

Coadministration of a Drug Treating the Disease Different from Alfuzosin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Ivosidenib.	Acute myeloid leukaemia [2A60]	[12]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Midostaurin.	Acute myeloid leukaemia [2A60]	[13]
Idarubicin	DMM0XGL	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Idarubicin.	Acute myeloid leukaemia [2A60]	[13]
Daunorubicin	DMQUSBT	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Daunorubicin.	Acute myeloid leukaemia [2A60]	[13]
Gilteritinib	DMTI0ZO	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Gilteritinib.	Acute myeloid leukaemia [2A60]	[14]
Oliceridine	DM6MDCF	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Oliceridine.	Acute pain [MG31]	[13]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Tacrine.	Alzheimer disease [8A20]	[13]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Rivastigmine.	Alzheimer disease [8A20]	[13]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Donepezil.	Alzheimer disease [8A20]	[13]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Alfuzosin and Metronidazole.	Amoebiasis [1A36]	[15]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Bepridil.	Angina pectoris [BA40]	[13]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Dronedarone.	Angina pectoris [BA40]	[13]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[16]
Hydroxyzine	DMF8Y74	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[13]
Promazine	DMZAL7W	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Promazine.	Appearance/behaviour symptom [MB23]	[13]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Cilostazol.	Arterial occlusive disease [BD40]	[13]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Alfuzosin caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[15]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Alfuzosin caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[15]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Levalbuterol.	Asthma [CA23]	[17]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Terbutaline.	Asthma [CA23]	[18]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Pirbuterol.	Asthma [CA23]	[18]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Salbutamol.	Asthma [CA23]	[17]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Formoterol.	Asthma [CA23]	[18]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[19]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[13]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[13]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Alfuzosin caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[11]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Alfuzosin and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[13]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Chloramphenicol	DMFXEWT	Moderate	Decreased metabolism of Alfuzosin caused by Chloramphenicol mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[11]
Linezolid	DMGFPU2	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Linezolid.	Bacterial infection [1A00-1C4Z]	[21]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Alfuzosin caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[13]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Alfuzosin caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[15]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Retigabine.	Behcet disease [4A62]	[13]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Cariprazine.	Bipolar disorder [6A60]	[22]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Loperamide.	Bowel habit change [ME05]	[23]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Lapatinib.	Breast cancer [2C60-2C6Y]	[13]
Tucatinib	DMBESUA	Major	Decreased metabolism of Alfuzosin caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Toremifene.	Breast cancer [2C60-2C6Y]	[13]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Bosutinib.	Breast cancer [2C60-2C6Y]	[19]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Sotalol.	Cardiac arrhythmia [BC9Z]	[13]
PF-04449913	DMSB068	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[24]
Olodaterol	DM62B78	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[18]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Oxaliplatin.	Colorectal cancer [2B91]	[13]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Isoproterenol.	Conduction disorder [BC63]	[17]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Alfuzosin and Olopatadine.	Conjunctiva disorder [9A60]	[25]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Halothane.	Corneal disease [9A76-9A78]	[13]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Propofol.	Corneal disease [9A76-9A78]	[26]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Probucol.	Coronary atherosclerosis [BA80]	[13]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Clofazimine.	Crohn disease [DD70]	[27]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Pasireotide.	Cushing syndrome [5A70]	[13]
Osilodrostat	DMIJC9X	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Osilodrostat.	Cushing syndrome [5A70]	[19]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Alfuzosin caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[28]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Alfuzosin caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[11]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Alfuzosin caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[11]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Sertraline.	Depression [6A70-6A7Z]	[13]
Trimipramine	DM1SC8M	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Trimipramine.	Depression [6A70-6A7Z]	[13]
Imipramine	DM2NUH3	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Imipramine.	Depression [6A70-6A7Z]	[13]
Fluoxetine	DM3PD2C	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Fluoxetine.	Depression [6A70-6A7Z]	[13]
Nortriptyline	DM4KDYJ	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Nortriptyline.	Depression [6A70-6A7Z]	[13]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Alfuzosin caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[15]
Selegiline	DM6034S	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Selegiline.	Depression [6A70-6A7Z]	[21]
Isocarboxazid	DMAF1NB	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Isocarboxazid.	Depression [6A70-6A7Z]	[21]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Escitalopram.	Depression [6A70-6A7Z]	[13]
Tranylcypromine	DMGB5RE	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Tranylcypromine.	Depression [6A70-6A7Z]	[21]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Alfuzosin and OPC-34712.	Depression [6A70-6A7Z]	[22]
Phenelzine	DMHIDUE	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Phenelzine.	Depression [6A70-6A7Z]	[21]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Clomipramine.	Depression [6A70-6A7Z]	[13]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Trazodone.	Depression [6A70-6A7Z]	[29]
Amoxapine	DMKITQE	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Amoxapine.	Depression [6A70-6A7Z]	[13]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Doxepin.	Depression [6A70-6A7Z]	[13]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Maprotiline.	Depression [6A70-6A7Z]	[13]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[13]
Deutetrabenazine	DMUPFLI	Moderate	Additive CNS depression effects by the combination of Alfuzosin and Deutetrabenazine.	Dystonic disorder [8A02]	[30]
Ingrezza	DMVPLNC	Moderate	Additive CNS depression effects by the combination of Alfuzosin and Ingrezza.	Dystonic disorder [8A02]	[31]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Alfuzosin caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Timolol	DM3NXRU	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Timolol.	Essential hypertension [BA00]	[32]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Phenoxybenzamine.	Essential hypertension [BA00]	[11]
Nadolol	DMW6GVL	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Nadolol.	Essential hypertension [BA00]	[32]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Solifenacin.	Functional bladder disorder [GC50]	[13]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Pentamidine.	Fungal infection [1F29-1F2F]	[13]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Alfuzosin caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[15]
Phentolamine	DMXYJOB	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Phentolamine.	Gangrene [MC85]	[11]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[13]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[13]
Carteolol	DMFMDOB	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Carteolol.	Glaucoma [9C61]	[32]
Metipranolol	DMJMVKI	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Metipranolol.	Glaucoma [9C61]	[32]
Levobetaxolol	DMSREPX	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Levobetaxolol.	Glaucoma [9C61]	[32]
Levobunolol	DMTNFCQ	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Levobunolol.	Glaucoma [9C61]	[32]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Prazosin.	Heart failure [BD10-BD1Z]	[11]
Carvedilol	DMHTEAO	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Carvedilol.	Heart failure [BD10-BD1Z]	[32]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Alfuzosin caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Telaprevir	DMMRV29	Major	Decreased metabolism of Alfuzosin caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[15]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Alfuzosin caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[33]
Procarbazine	DMIK367	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Procarbazine.	Hodgkin lymphoma [2B30]	[21]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Alfuzosin caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Alfuzosin caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Alfuzosin caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[34]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[35]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Alfuzosin caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[13]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Alfuzosin caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Alfuzosin caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Ritonavir	DMU764S	Major	Decreased metabolism of Alfuzosin caused by Ritonavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Acebutolol	DM0TI4U	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Acebutolol.	Hypertension [BA00-BA04]	[32]
Moexipril	DM26E4B	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Moexipril.	Hypertension [BA00-BA04]	[37]
Bisoprolol	DM3UZ95	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Bisoprolol.	Hypertension [BA00-BA04]	[32]
Captopril	DM458UM	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Captopril.	Hypertension [BA00-BA04]	[37]
Penbutolol	DM4ES8F	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Penbutolol.	Hypertension [BA00-BA04]	[32]
Trandolapril	DM4L6EU	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Trandolapril.	Hypertension [BA00-BA04]	[37]
Nebivolol	DM7F1PA	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Nebivolol.	Hypertension [BA00-BA04]	[32]
Fosinopril	DM9NJ52	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Fosinopril.	Hypertension [BA00-BA04]	[37]
Doxazosin	DM9PLRH	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Doxazosin.	Hypertension [BA00-BA04]	[11]
Pindolol	DMD2NV7	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Pindolol.	Hypertension [BA00-BA04]	[32]
Benazepril	DMH1M9B	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Benazepril.	Hypertension [BA00-BA04]	[37]
Labetalol	DMK8U72	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Labetalol.	Hypertension [BA00-BA04]	[32]
Enalapril	DMNFUZR	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Enalapril.	Hypertension [BA00-BA04]	[37]
Perindopril	DMOPZDT	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Perindopril.	Hypertension [BA00-BA04]	[37]
Quinapril	DMR8H31	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Quinapril.	Hypertension [BA00-BA04]	[37]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Alfuzosin caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[11]
Propiomazine	DMKY8V1	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Propiomazine.	Insomnia [7A00-7A0Z]	[22]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Alfuzosin and ITI-007.	Insomnia [7A00-7A0Z]	[22]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[19]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Phenolphthalein.	Irritable bowel syndrome [DD91]	[13]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Crizotinib.	Lung cancer [2C25]	[38]
Ceritinib	DMB920Z	Major	Decreased metabolism of Alfuzosin caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Alfuzosin caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[39]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Osimertinib.	Lung cancer [2C25]	[40]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Selpercatinib.	Lung cancer [2C25]	[19]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Halofantrine.	Malaria [1F40-1F45]	[41]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Chloroquine.	Malaria [1F40-1F45]	[42]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Hydroxychloroquine.	Malaria [1F40-1F45]	[42]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Quinine.	Malaria [1F40-1F45]	[13]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Primaquine.	Malaria [1F40-1F45]	[13]
Mefloquine	DMWT905	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Mefloquine.	Malaria [1F40-1F45]	[13]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[19]
Idelalisib	DM602WT	Major	Decreased metabolism of Alfuzosin caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[15]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Alfuzosin caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[11]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[43]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Vemurafenib.	Melanoma [2C30]	[13]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and LGX818.	Melanoma [2C30]	[44]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Alfuzosin caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[19]
Danazol	DML8KTN	Moderate	Decreased metabolism of Alfuzosin caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[11]
Propranolol	DM79NTF	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Propranolol.	Migraine [8A80]	[32]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Alfuzosin caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[45]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Panobinostat.	Multiple myeloma [2A83]	[46]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Thalidomide.	Multiple myeloma [2A83]	[15]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Fingolimod.	Multiple sclerosis [8A40]	[13]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Ozanimod.	Multiple sclerosis [8A40]	[47]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Alfuzosin caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[11]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Alfuzosin caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[11]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Dasatinib.	Myeloproliferative neoplasm [2A20]	[13]
Modafinil	DMYILBE	Minor	Increased metabolism of Alfuzosin caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[48]
Prochlorperazine	DM53SRA	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Prochlorperazine.	Nausea/vomiting [MD90]	[13]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Promethazine.	Nausea/vomiting [MD90]	[22]
Palonosetron	DMBHMOX	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Palonosetron.	Nausea/vomiting [MD90]	[13]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Granisetron.	Nausea/vomiting [MD90]	[13]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Dolasetron.	Nausea/vomiting [MD90]	[13]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Ondansetron.	Nausea/vomiting [MD90]	[13]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Entrectinib.	Non-small cell lung cancer [2C25]	[15]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Levomethadyl Acetate.	Opioid use disorder [6C43]	[19]
Lofexidine	DM1WXA6	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Lofexidine.	Opioid use disorder [6C43]	[13]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Rucaparib.	Ovarian cancer [2C73]	[13]
Dextropropoxyphene	DM23HCX	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Dextropropoxyphene.	Pain [MG30-MG3Z]	[13]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Buprenorphine.	Pain [MG30-MG3Z]	[13]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Triclabendazole.	Parasitic worm infestation [1F90]	[13]
Safinamide	DM0YWJC	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Safinamide.	Parkinsonism [8A00]	[21]
Rasagiline	DM3WKQ4	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Rasagiline.	Parkinsonism [8A00]	[21]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Pimavanserin.	Parkinsonism [8A00]	[49]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Apomorphine.	Parkinsonism [8A00]	[13]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Alfuzosin caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[50]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Famotidine.	Peptic ulcer [DA61]	[15]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Lefamulin.	Pneumonia [CA40]	[51]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Alfuzosin caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[15]
Ritodrine	DM4V6RL	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Ritodrine.	Preterm labour/delivery [JB00]	[18]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Degarelix.	Prostate cancer [2C82]	[19]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and ABIRATERONE.	Prostate cancer [2C82]	[19]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Nilutamide.	Prostate cancer [2C82]	[19]
Enzalutamide	DMGL19D	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Enzalutamide.	Prostate cancer [2C82]	[19]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Flutamide.	Prostate cancer [2C82]	[19]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Bicalutamide.	Prostate cancer [2C82]	[19]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Levomepromazine.	Psychotic disorder [6A20-6A25]	[13]
Fluphenazine	DMIT8LX	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Fluphenazine.	Psychotic disorder [6A20-6A25]	[13]
Triflupromazine	DMKFQJP	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Triflupromazine.	Psychotic disorder [6A20-6A25]	[13]
Tolazoline	DMI40NL	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Tolazoline.	Pulmonary hypertension [BB01]	[11]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Sorafenib.	Renal cell carcinoma [2C90]	[13]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[52]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Mesoridazine.	Schizophrenia [6A20]	[13]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Thioridazine.	Schizophrenia [6A20]	[13]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Aripiprazole.	Schizophrenia [6A20]	[22]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Iloperidone.	Schizophrenia [6A20]	[13]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Paliperidone.	Schizophrenia [6A20]	[53]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Loxapine.	Schizophrenia [6A20]	[22]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Haloperidol.	Schizophrenia [6A20]	[13]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Perphenazine.	Schizophrenia [6A20]	[13]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Molindone.	Schizophrenia [6A20]	[22]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Chlorpromazine.	Schizophrenia [6A20]	[13]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Thiothixene.	Schizophrenia [6A20]	[22]
Clozapine	DMFC71L	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Clozapine.	Schizophrenia [6A20]	[13]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Trifluoperazine.	Schizophrenia [6A20]	[13]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Risperidone.	Schizophrenia [6A20]	[53]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Amisulpride.	Schizophrenia [6A20]	[54]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Asenapine.	Schizophrenia [6A20]	[13]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Pimozide.	Schizophrenia [6A20]	[19]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Alfuzosin caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Armodafinil	DMGB035	Minor	Increased metabolism of Alfuzosin caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[48]
LEE011	DMMX75K	Major	Decreased metabolism of Alfuzosin caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[13]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[13]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[13]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[19]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[13]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Pitolisant.	Somnolence [MG42]	[19]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[13]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Alfuzosin and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[13]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Alfuzosin caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[55]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Lenvatinib.	Thyroid cancer [2D10]	[13]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Cabozantinib.	Thyroid cancer [2D10]	[19]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Papaverine.	Tonus and reflex abnormality [MB47]	[56]
Tizanidine	DMR2IQ4	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Tizanidine.	Tonus and reflex abnormality [MB47]	[11]
Tacrolimus	DMZ7XNQ	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Tacrolimus.	Transplant rejection [NE84]	[13]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[13]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Alfuzosin and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[22]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[13]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Procainamide.	Ventricular tachyarrhythmia [BC71]	[13]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Propafenone.	Ventricular tachyarrhythmia [BC71]	[13]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Alfuzosin and Flecainide.	Ventricular tachyarrhythmia [BC71]	[13]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Alfuzosin and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[13]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite	E00392	104805	Diluent
Calcium hydrogenphosphate	E00294	24441	Diluent
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Alfuzosin 10 mg tablet	10 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7109).
• [2] Alfuzosin FDA Label
• [3] FDA Approved Drug Products: Alfuzosin Extended Release Tablets
• [4] BDDCS applied to over 900 drugs
• [5] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [6] Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
• [7] Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs. 2002;62(4):633-53.
• [8] In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 2011;(201):325-71.
• [9] Cell membrane chromatography competitive binding analysis for characterization of 1A adrenoreceptor binding interactions. Anal Bioanal Chem. 2011 Jul;400(10):3625-33. doi: 10.1007/s00216-011-5026-z. Epub 2011 May 5.
• [10] The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype. Mol Pharmacol. 1994 Apr;45(4):703-8.
• [11] Product Information. Uroxatral (alfuzosin). sanofi-aventis , Bridgewater, NJ.
• [12] Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
• [13] Canadian Pharmacists Association.
• [14] Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
• [15] Cerner Multum, Inc. "Australian Product Information.".
• [16] Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
• [17] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [18] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [19] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [20] Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
• [21] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
• [22] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
• [23] Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
• [24] Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [25] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
• [26] Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
• [27] Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
• [28] Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
• [29] Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
• [30] Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
• [31] Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
• [32] Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
• [33] Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [34] Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
• [35] Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
• [36] Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
• [37] Baba T, Tomiyama T, Takebe K "Enhancement by an ACE inhibitor of first-dose hypotension caused by an alpha-blocker." N Engl J Med 322 (1990): 1237. [PMID: 1970122]
• [38] Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [39] Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
• [40] Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
• [41] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
• [42] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
• [43] Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
• [44] Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
• [45] Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
• [46] Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
• [47] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [48] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
• [49] Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
• [50] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [51] Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
• [52] Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
• [53] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9. [PMID: 7663034]
• [54] Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
• [55] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
• [56] Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]